Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity

Michael M. Ndengele, Salvatore Cuzzocrea, Emanuela Esposito, Emanuela Mazzon, Rosanna Di Paola, George M. Matuschak, Daniela Salvemini

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Peroxynitrite (ONOO-), the reaction product of the interaction between superoxide (O2·-) and nitric oxide (·NO), is a potent proinflammatory and cytotoxic nitrooxidative species. Its role as a mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) is not known. In light of the known proinflammatory properties of ONOO-, our study addressed its potential involvement in the development of hyperalgesia associated with tissue damage and inflammation. Intraplantar injection in rats of the ONOO- precursor O2·- (1 μM) led to the development of thermal hyperalgesia associated with a profound localized inflammatory response. Both events were blocked by L-NAME (NG-nitro-L-arginine methyl ester, 3-30 mg/kg), a nitric oxide synthase inhibitor, or by FeTM-4-PyP 5+ [Fe(III)5,10,15,20-tetrakis(N-methylpyridinium-4-yl)porphyrin, 3-30 mg/kg], an ONOO- decomposition catalyst. These results suggested that locally synthesized ONOO- produced in situ by O 2·- and ·NO is key in the development of inflammatory hyperalgesia. The direct link between ONOO- and hyperalgesia was further supported by demonstrating that intraplantar injection of soluble ONOO- itself (1 μM) similarly led to inflammatory hyperalgesia. ONOO- generated by the interaction between exogenous administration of O2·- and endogenous ·NO, or provided by direct injection of ONOO-, activated the transcription factor NF-κB in paw tissues, enhancing expression of the inducible but not the constitutive cyclooxygenase enzyme (COX-2 and COX-1, respectively). ONOO--mediated hyperalgesia was blocked in a dose-dependent manner by intraperitoneal injections of indomethacin (10 mg/kg), a nonselective COX-1/ COX-2 inhibitor, or NS398 [N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide; 10 mg/kg] a selective COX-2 inhibitor, as well as by an anti-prostaglandin (PG) E2 antibody (200 μg). In another established model of inflammation-related hyperalgesia by intraplantar injection of carrageenan in rats, inhibition of ONOO- with FeTM-4-PyP5+ (3-30 mg/kg) inhibited the development of hyperalgesia and the release of PGE2 in paw tissue exudates. Furthermore, FeTM-4-PyP5+ synergized with indomethacin and NS397 (1-10 mg/kg) to block both hyperalgesia and edema. Taken together, these data show for the first time that ONOO- is a potent mediator of inflammation-derived hyperalgesia operating via the COX-to-PGE 2 pathway. These results provide a pharmacological rationale for the development of inhibitors of peroxynitrite biosynthesis as novel nonnarcotic analgesics. The broad implications of our study are that dual inhibition of both ONOO- formation and COX activity may provide an alternative therapeutic approach to the management of pain: effective analgesia with reduced side-effects typically associated with the use of COX inhibitors.

Original languageEnglish
Pages (from-to)3154-3164
Number of pages11
JournalFASEB Journal
Volume22
Issue number9
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Cyclooxygenase 1
Peroxynitrous Acid
Hyperalgesia
prostaglandin synthase
Cyclooxygenase 2
hypersensitivity
pain
Hypersensitivity
Nitric Oxide
Cyclooxygenase 2 Inhibitors
NG-Nitroarginine Methyl Ester
Tissue
Dinoprostone
Pain
Indomethacin
Rats
inflammation
Non-Narcotic Analgesics
injection
nitric oxide

Keywords

  • COX-1
  • COX-2
  • Hyperalgesia
  • Nitric oxide
  • PGE
  • Superoxide

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Ndengele, M. M., Cuzzocrea, S., Esposito, E., Mazzon, E., Di Paola, R., Matuschak, G. M., & Salvemini, D. (2008). Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. FASEB Journal, 22(9), 3154-3164. https://doi.org/10.1096/fj.08-108159

Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. / Ndengele, Michael M.; Cuzzocrea, Salvatore; Esposito, Emanuela; Mazzon, Emanuela; Di Paola, Rosanna; Matuschak, George M.; Salvemini, Daniela.

In: FASEB Journal, Vol. 22, No. 9, 09.2008, p. 3154-3164.

Research output: Contribution to journalArticle

Ndengele, MM, Cuzzocrea, S, Esposito, E, Mazzon, E, Di Paola, R, Matuschak, GM & Salvemini, D 2008, 'Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity', FASEB Journal, vol. 22, no. 9, pp. 3154-3164. https://doi.org/10.1096/fj.08-108159
Ndengele, Michael M. ; Cuzzocrea, Salvatore ; Esposito, Emanuela ; Mazzon, Emanuela ; Di Paola, Rosanna ; Matuschak, George M. ; Salvemini, Daniela. / Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. In: FASEB Journal. 2008 ; Vol. 22, No. 9. pp. 3154-3164.
@article{509826b8f80241d89a19eef1acef4208,
title = "Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity",
abstract = "Peroxynitrite (ONOO-), the reaction product of the interaction between superoxide (O2·-) and nitric oxide (·NO), is a potent proinflammatory and cytotoxic nitrooxidative species. Its role as a mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) is not known. In light of the known proinflammatory properties of ONOO-, our study addressed its potential involvement in the development of hyperalgesia associated with tissue damage and inflammation. Intraplantar injection in rats of the ONOO- precursor O2·- (1 μM) led to the development of thermal hyperalgesia associated with a profound localized inflammatory response. Both events were blocked by L-NAME (NG-nitro-L-arginine methyl ester, 3-30 mg/kg), a nitric oxide synthase inhibitor, or by FeTM-4-PyP 5+ [Fe(III)5,10,15,20-tetrakis(N-methylpyridinium-4-yl)porphyrin, 3-30 mg/kg], an ONOO- decomposition catalyst. These results suggested that locally synthesized ONOO- produced in situ by O 2·- and ·NO is key in the development of inflammatory hyperalgesia. The direct link between ONOO- and hyperalgesia was further supported by demonstrating that intraplantar injection of soluble ONOO- itself (1 μM) similarly led to inflammatory hyperalgesia. ONOO- generated by the interaction between exogenous administration of O2·- and endogenous ·NO, or provided by direct injection of ONOO-, activated the transcription factor NF-κB in paw tissues, enhancing expression of the inducible but not the constitutive cyclooxygenase enzyme (COX-2 and COX-1, respectively). ONOO--mediated hyperalgesia was blocked in a dose-dependent manner by intraperitoneal injections of indomethacin (10 mg/kg), a nonselective COX-1/ COX-2 inhibitor, or NS398 [N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide; 10 mg/kg] a selective COX-2 inhibitor, as well as by an anti-prostaglandin (PG) E2 antibody (200 μg). In another established model of inflammation-related hyperalgesia by intraplantar injection of carrageenan in rats, inhibition of ONOO- with FeTM-4-PyP5+ (3-30 mg/kg) inhibited the development of hyperalgesia and the release of PGE2 in paw tissue exudates. Furthermore, FeTM-4-PyP5+ synergized with indomethacin and NS397 (1-10 mg/kg) to block both hyperalgesia and edema. Taken together, these data show for the first time that ONOO- is a potent mediator of inflammation-derived hyperalgesia operating via the COX-to-PGE 2 pathway. These results provide a pharmacological rationale for the development of inhibitors of peroxynitrite biosynthesis as novel nonnarcotic analgesics. The broad implications of our study are that dual inhibition of both ONOO- formation and COX activity may provide an alternative therapeutic approach to the management of pain: effective analgesia with reduced side-effects typically associated with the use of COX inhibitors.",
keywords = "COX-1, COX-2, Hyperalgesia, Nitric oxide, PGE, Superoxide",
author = "Ndengele, {Michael M.} and Salvatore Cuzzocrea and Emanuela Esposito and Emanuela Mazzon and {Di Paola}, Rosanna and Matuschak, {George M.} and Daniela Salvemini",
year = "2008",
month = "9",
doi = "10.1096/fj.08-108159",
language = "English",
volume = "22",
pages = "3154--3164",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "9",

}

TY - JOUR

T1 - Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity

AU - Ndengele, Michael M.

AU - Cuzzocrea, Salvatore

AU - Esposito, Emanuela

AU - Mazzon, Emanuela

AU - Di Paola, Rosanna

AU - Matuschak, George M.

AU - Salvemini, Daniela

PY - 2008/9

Y1 - 2008/9

N2 - Peroxynitrite (ONOO-), the reaction product of the interaction between superoxide (O2·-) and nitric oxide (·NO), is a potent proinflammatory and cytotoxic nitrooxidative species. Its role as a mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) is not known. In light of the known proinflammatory properties of ONOO-, our study addressed its potential involvement in the development of hyperalgesia associated with tissue damage and inflammation. Intraplantar injection in rats of the ONOO- precursor O2·- (1 μM) led to the development of thermal hyperalgesia associated with a profound localized inflammatory response. Both events were blocked by L-NAME (NG-nitro-L-arginine methyl ester, 3-30 mg/kg), a nitric oxide synthase inhibitor, or by FeTM-4-PyP 5+ [Fe(III)5,10,15,20-tetrakis(N-methylpyridinium-4-yl)porphyrin, 3-30 mg/kg], an ONOO- decomposition catalyst. These results suggested that locally synthesized ONOO- produced in situ by O 2·- and ·NO is key in the development of inflammatory hyperalgesia. The direct link between ONOO- and hyperalgesia was further supported by demonstrating that intraplantar injection of soluble ONOO- itself (1 μM) similarly led to inflammatory hyperalgesia. ONOO- generated by the interaction between exogenous administration of O2·- and endogenous ·NO, or provided by direct injection of ONOO-, activated the transcription factor NF-κB in paw tissues, enhancing expression of the inducible but not the constitutive cyclooxygenase enzyme (COX-2 and COX-1, respectively). ONOO--mediated hyperalgesia was blocked in a dose-dependent manner by intraperitoneal injections of indomethacin (10 mg/kg), a nonselective COX-1/ COX-2 inhibitor, or NS398 [N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide; 10 mg/kg] a selective COX-2 inhibitor, as well as by an anti-prostaglandin (PG) E2 antibody (200 μg). In another established model of inflammation-related hyperalgesia by intraplantar injection of carrageenan in rats, inhibition of ONOO- with FeTM-4-PyP5+ (3-30 mg/kg) inhibited the development of hyperalgesia and the release of PGE2 in paw tissue exudates. Furthermore, FeTM-4-PyP5+ synergized with indomethacin and NS397 (1-10 mg/kg) to block both hyperalgesia and edema. Taken together, these data show for the first time that ONOO- is a potent mediator of inflammation-derived hyperalgesia operating via the COX-to-PGE 2 pathway. These results provide a pharmacological rationale for the development of inhibitors of peroxynitrite biosynthesis as novel nonnarcotic analgesics. The broad implications of our study are that dual inhibition of both ONOO- formation and COX activity may provide an alternative therapeutic approach to the management of pain: effective analgesia with reduced side-effects typically associated with the use of COX inhibitors.

AB - Peroxynitrite (ONOO-), the reaction product of the interaction between superoxide (O2·-) and nitric oxide (·NO), is a potent proinflammatory and cytotoxic nitrooxidative species. Its role as a mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) is not known. In light of the known proinflammatory properties of ONOO-, our study addressed its potential involvement in the development of hyperalgesia associated with tissue damage and inflammation. Intraplantar injection in rats of the ONOO- precursor O2·- (1 μM) led to the development of thermal hyperalgesia associated with a profound localized inflammatory response. Both events were blocked by L-NAME (NG-nitro-L-arginine methyl ester, 3-30 mg/kg), a nitric oxide synthase inhibitor, or by FeTM-4-PyP 5+ [Fe(III)5,10,15,20-tetrakis(N-methylpyridinium-4-yl)porphyrin, 3-30 mg/kg], an ONOO- decomposition catalyst. These results suggested that locally synthesized ONOO- produced in situ by O 2·- and ·NO is key in the development of inflammatory hyperalgesia. The direct link between ONOO- and hyperalgesia was further supported by demonstrating that intraplantar injection of soluble ONOO- itself (1 μM) similarly led to inflammatory hyperalgesia. ONOO- generated by the interaction between exogenous administration of O2·- and endogenous ·NO, or provided by direct injection of ONOO-, activated the transcription factor NF-κB in paw tissues, enhancing expression of the inducible but not the constitutive cyclooxygenase enzyme (COX-2 and COX-1, respectively). ONOO--mediated hyperalgesia was blocked in a dose-dependent manner by intraperitoneal injections of indomethacin (10 mg/kg), a nonselective COX-1/ COX-2 inhibitor, or NS398 [N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide; 10 mg/kg] a selective COX-2 inhibitor, as well as by an anti-prostaglandin (PG) E2 antibody (200 μg). In another established model of inflammation-related hyperalgesia by intraplantar injection of carrageenan in rats, inhibition of ONOO- with FeTM-4-PyP5+ (3-30 mg/kg) inhibited the development of hyperalgesia and the release of PGE2 in paw tissue exudates. Furthermore, FeTM-4-PyP5+ synergized with indomethacin and NS397 (1-10 mg/kg) to block both hyperalgesia and edema. Taken together, these data show for the first time that ONOO- is a potent mediator of inflammation-derived hyperalgesia operating via the COX-to-PGE 2 pathway. These results provide a pharmacological rationale for the development of inhibitors of peroxynitrite biosynthesis as novel nonnarcotic analgesics. The broad implications of our study are that dual inhibition of both ONOO- formation and COX activity may provide an alternative therapeutic approach to the management of pain: effective analgesia with reduced side-effects typically associated with the use of COX inhibitors.

KW - COX-1

KW - COX-2

KW - Hyperalgesia

KW - Nitric oxide

KW - PGE

KW - Superoxide

UR - http://www.scopus.com/inward/record.url?scp=51349102582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349102582&partnerID=8YFLogxK

U2 - 10.1096/fj.08-108159

DO - 10.1096/fj.08-108159

M3 - Article

C2 - 18497304

AN - SCOPUS:51349102582

VL - 22

SP - 3154

EP - 3164

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 9

ER -